Glaxo's Zofran
Executive Summary
Glaxo is pricing the oral formulation of the antiemetic at an AWP of $314.70 for 30 4 mg tablets, Medi-Span reports. Oral Zofran (ondansetron) was approved Dec. 31 for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, one year after the injectable version cleared FDA ("The Pink Sheet" Jan. 4, 1993, p. 2).